FONT-SIZE Plus   Neg

XARELTO Found As Effective As Standard Treatment In VTE Trial - Quick Facts

Janssen Research & Development LLC reported results of the EINSTEIN-PE study, demonstrating that the oral anticoagulant XARELTO or rivaroxaban was comparable to today's standard of care in treating patients with acute symptomatic pulmonary embolism or PE and in preventing secondary venous blood clot development, also called as venous thromboembolism or VTE. Further, the study discovered that rivaroxaban had a similar safety profile and significantly lower risk of major bleeding versus the current standard regimen.

The EINSTEIN-PE study compared rivaroxaban to enoxaparin followed by vitamin K antagonist in the treatment of 4,833 patients with acute symptomatic PE for the prevention of recurrent VTE. Patients received treatment for three, six or 12 months. As a result of the study, rivaroxaban showed non-inferiority to standard therapy for the primary endpoint of recurrent symptomatic VTE, a composite of symptomatic deep vein thrombosis or DVT and non-fatal or fatal PE. In addition, Rivaroxaban demonstrated similar results compared to standard of care for the principal safety outcome measuring a composite of major and non-major clinically relevant bleeding events.

Rivaroxaban treatment also resulted in a significant reduction in major bleeding events versus standard therapy. VTE is the collective term for both deep vein thrombosis or DVT and PE. The company intends to file the EINSTEIN studies in a supplemental New Drug Application with the FDA during the second quarter of this year. Janssen Research & Development LLC and Janssen Pharmaceuticals Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ).

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Earnings at banking giant JP Morgan Chase (JPM) jumped more than 20% compared to last year, despite a decline in revenue. The firm's bottom line received a boost from about $2 billion in tax benefits. Computer chip maker Intel (INTC) announced earnings for the third quarter that slipped about 6 percent from last year. Still, the bottom line came in above the amount predicted by market analysts, as Wall Street had predicted a more pronounced decline. Intel benefited from gains in its Data Center and Internet units, but saw year-over-year weakness in its Client Computing division. Starbucks is rolling out its delivery service - good news for any caffeine addicts who can't make it out to the coffee chain. Unfortunately, there's still a wait in store for most people: the new service only covers Manhattan's most recognizable skyscraper. According to multiple media reports, Starbucks' pilot program is launching at the Empire State Building in New York City.
comments powered by Disqus
Trade JNJ now with 
Follow RTT